What Are GLP-1s?
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally releases after eating.
Its primary role is regulating metabolism.
GLP-1 helps:
- Control blood sugar
- Slow stomach emptying
- Signal fullness to the brain
- Support insulin release
GLP-1 medications are designed to mimic this natural hormone.
Common examples:
- Semaglutide (Ozempic, Wegovy)
- Tirzepatide (Mounjaro, Zepbound)
- Liraglutide (Saxenda, Victoza)
These medications were originally developed to treat type 2 diabetes. Significant weight loss later emerged as an important secondary benefit.
How Do They Work?
GLP-1 medications improve how the body processes energy and regulates appetite.
They can:
- Reduce appetite
- Improve insulin sensitivity
- Stabilize blood sugar
- Promote weight loss
- Improve overall metabolic health
Emerging research suggests GLP-1s may also influence inflammatory signaling within immune cells. However, this relationship is still being studied.
I’ll publish a deeper biology breakdown on the blog this week if you want to explore the science further.
|
What Are GLP-1s Approved For?
Currently, GLP-1 medications are approved for:
- Type 2 diabetes
- Chronic weight management
- Cardiovascular risk reduction in select patients
They are not currently approved as treatments for rheumatoid arthritis.
What Does the Research Say About RA?
At this point, there are no large randomized clinical trials showing that GLP-1 medications treat rheumatoid arthritis directly.
What we do have includes:
- Small observational studies showing symptom improvement in some patients with obesity
- Reductions in certain inflammatory markers
- Laboratory research suggesting possible immune signaling effects
There are important limitations worth understanding.
Most studies involve small sample sizes, observational data, and limited long-term autoimmune outcomes.
GLP-1 medications do not prevent rheumatoid arthritis, and they are not considered disease-modifying treatments.
So are GLP-1s truly anti-inflammatory for RA?
Possibly — but likely indirectly.
Right now, it is more accurate to think of them as metabolic medications that may influence inflammation secondarily.
Why Weight Loss Can Matter in RA
Body fat is not just stored energy. It is metabolically active tissue.
Adipose tissue produces inflammatory cytokines such as TNF-alpha and IL-6, both of which play major roles in rheumatoid arthritis.
Higher body fat levels are associated with:
- Increased disease activity
- More pain
- Lower remission rates
- Higher cardiovascular risk
When metabolic inflammation improves, symptoms may improve as well.
But this is different from directly suppressing autoimmune disease.
Dosing Basics
Most GLP-1 medications are taken as once-weekly injections and are slowly increased over time to reduce side effects.
Common side effects may include:
- Nausea
- Constipation
- Delayed stomach emptying
- Reduced appetite
Less common concerns include:
- Gallbladder issues
- Muscle loss if protein intake and strength training are inadequate
These medications should always be used under medical supervision.
Who Might Consider a GLP-1?
GLP-1 therapy may be worth discussing with your physician if you have:
- RA combined with obesity
- Insulin resistance or metabolic syndrome
- Elevated cardiovascular risk
- Difficulty losing weight despite structured efforts
Improving metabolic health may reduce overall inflammatory burden in some patients.
Who Might Not Benefit
GLP-1 medications may be less appropriate for:
- Normal BMI patients
- Stable RA remission
- Those unable to tolerate GI side effects
- Individuals seeking a direct RA treatment
GLP-1s do not replace DMARDs or biologic therapy.
